Managing Director
and access,
Dr. Glazer is a Managing Director with Outcome Capital, bringing nearly 30 years of experience in clinical R&D, medical and regulatory affairs, commercial, market access and other areas across a variety of medical technology and biopharmaceutical segments. Before Joining Outcome, Dr. Glezer, was with Inogen Inc, a medical technology company offering innovative respiratory products for use in the homecare setting, where he served as an Executive Vice President, R&D and Chief Medical Officer. Under his leadership, the company has secured an MDR certification, developed and obtained 510k clearance for a couple of innovative devices, acquired of a French medical technology company, and completed several clinical trials and Real World Evidence projects, resulting in peer reviewed publications and posters at international conferences. Prior to Inogen, Dr. Glezer worked for Becton, Dickinson and Company, a global medical technology company where he served as the Worldwide Vice President of Medical Affairs for Diabetes Care since September 2018 with Business Development responsibilities added under him since January 2021. He was also leading Medical Affairs activities for Pharmaceutical Systems BU and led the clinical trial program for Sample Management BU. Prior to joining Becton Dickinson, Dr. Glezer served as the Chief Medical Officer at Adocia S.A. a biotechnology company, from 2017 to 2018. From 2016 to 2017, Dr. Glezer served as Vice President of Global Medical Affairs at Novo Nordisk, Inc., a healthcare company. Earlier, Dr. Glezer served in a number of roles of progressively increasing seniority, including, Global Project Head for the largest late-stage pipeline asset, Vice President of Evidence and Value & Access, Vice President of Medical Affairs, and Senior Director of Medical Strategy & Operations, for Sanofi S.A., a multinational pharmaceutical company, from 2001 to 2015. Dr. Glezer holds a Doctor of Medicine with Honors from Moscow State University of Medicine and Dentistry and an MBA from California Coast University. He has completed training in Health Economics and Clinical Research at McGill University and is currently participating in the CEO Program at Columbia University Business School. He is a FINRA Registered Securities Representative holding Series 79 and 63 registrations.
